Machine learning approaches to drug response prediction: challenges and recent progress (original) (raw)

• Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21492 (2018).
• Cronin, K. A. et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 124, 2785–2800 (2018).
  Article PubMed Google Scholar
• Garraway, L. A., Verweij, J. & Ballman, K. V. Precision oncology: an overview. J. Clin. Oncol. 31, 1803–1805 (2013).
  Article PubMed Google Scholar
• Doherty, M., Metcalfe, T., Guardino, E., Peters, E. & Ramage, L. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 27, 1644–1646 (2016).
  Article CAS PubMed Google Scholar
• Heymach, J. et al. Clinical Cancer Advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 36, 1020–1044 (2018).
  Article PubMed Google Scholar
• Twomey, J. D., Brahme, N. N. & Zhang, B. Drug-biomarker co-development in oncology—20 years and counting. Drug Resist. Updat 30, 48–62 (2017).
  Article PubMed Google Scholar
• Johnson, A. et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov. Today 20, 1433–1438 (2015).
  Article PubMed PubMed Central Google Scholar
• Prasad, V., Kaestner, V. & Mailankody, S. Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 4, 157–158 (2018).
  Article PubMed Google Scholar
• Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Drilon, A. et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F. & Tejpar, S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12, 594–603 (2011).
  Article PubMed CAS Google Scholar
• Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D. & Lu, X. Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of cancer cells to effective therapeutics. Mol. Cancer Res. 16, 269–278 (2018).
  Article CAS PubMed Google Scholar
• Perez-Gracia, J. L. et al. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat. Rev. 53, 79–97 (2017).
  Article PubMed Google Scholar
• Dhandapani, M. & Goldman, A. Preclinical cancer models and biomarkers for drug development: new technologies and emerging tools. J. Mol. Biomark. Diagn. 8, 356 (2017).
• Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813–823 (2006).
  Article CAS PubMed Google Scholar
• Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188–195 (2011).
  Article CAS PubMed Google Scholar
• Smirnov, P. et al. PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids Res. 46, D994–D1002 (2018).
  Article CAS PubMed Google Scholar
• Ling, A., Gruener, R. F., Fessler, J. & Huang, R. S. More than fishing for a cure: the promises and pitfalls of high throughput cancer cell line screens. Pharmacol. Ther. https://doi.org/10.1016/j.pharmthera.2018.06.014 (2018).
• Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311–316 (2015).
  Article CAS PubMed Google Scholar
• Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325 (2015).
  Article CAS PubMed Google Scholar
• McVeigh, T. P. et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur. J. Cancer 50, 2763–2770 (2014).
  Article PubMed PubMed Central Google Scholar
• Slodkowska, E. A. & Ross, J. S. MammaPrintTM 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev. Mol. Diagn. 9, 417–422 (2009).
  Article PubMed Google Scholar
• Azuaje, F. Computational models for predicting drug responses in cancer research. Brief. Bioinform. 18, 820–829 (2017).
  CAS PubMed Google Scholar
• De Niz, C., Rahman, R., Zhao, X. & Pal, R. Algorithms for drug sensitivity prediction. Algorithms 9, 77 (2016).
  Article Google Scholar
• Iorio, F. et al. A landscape of pharmacogenomic interactions in cell. Cell 166, 740–754 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Safikhani, Z. et al. Gene isoforms as expression-based biomarkers predictive of drug response in vitro. Nat. Commun. 8, 1126 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Jang, I. S., Neto, E. C., Guinney, J., Friend, S. H. & Margolin, A. A. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pac. Symp. Biocomput. 19, 63–74 (2014).
• Stetson, L. C., Pearl, T., Chen, Y. & Barnholtz-Sloan, J. S. Computational identification of multi-omic correlates of anticancer therapeutic response. BMC Genomics 15(Suppl. 7), S2 (2014).
  Article PubMed PubMed Central Google Scholar
• Costello, J. C. et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat. Biotechnol. 32, 1202–1212 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Menden, M. P. et al. A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction. bioRxiv 200451. https://doi.org/10.1101/200451 (2018).
• Papillon-Cavanagh, S. et al. Comparison and validation of genomic predictors for anticancer drug sensitivity. J. Am. Med. Inform. Assoc. 20, 597–602 (2013).
  Article PubMed PubMed Central Google Scholar
• De Jay, N. et al. mRMRe: an R package for parallelized mRMR ensemble feature selection. Bioinformatics 29, 2365–2368 (2013).
  Article PubMed CAS Google Scholar
• Gönen, M. & Margolin, A. A. Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning. Bioinformatics 30, i556–i563 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Ammad-Ud-Din, M., Khan, S. A., Wennerberg, K. & Aittokallio, T. Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression. Bioinformatics 33, i359–i368 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Andersen, M. E., Yang, R. S. H., French, C. T., Chubb, L. S. & Dennison, J. E. Molecular circuits, biological switches, and nonlinear dose–response relationships. Environ. Health Perspect. 110(Suppl. 6), 971–978 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, S.-I. et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat. Commun. 9, 42 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Zhang, F., Wang, M., Xi, J., Yang, J. & Li, A. A novel heterogeneous network-based method for drug response prediction in cancer cell lines. Sci. Rep. 8, 3355 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, L., Li, X., Zhang, L. & Gao, Q. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer 17, 513 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• El-Deredy, W. et al. Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. Cancer Res. 57, 4196–4199 (1997).
  CAS PubMed Google Scholar
• Dahl, G. E., Jaitly, N. & Salakhutdinov, R. Multi-task neural networks for QSAR predictions. Preprint at https://arxiv.org/abs/1406.1231 (2014).
• Unterthiner, T. et al. Deep learning as an opportunity in virtual screening. in Proc. Deep Learning Workshop at NIPS, NeurIPS workshop, Vol. 27, 1–9 (2014).
• Aliper, A. et al. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol. Pharm. 13, 2524–2530 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Gilmer, J., Schoenholz, S. S., Riley, P. F., Vinyals, O. & Dahl, G. E. Neural message passing for Quantum chemistry. in Proceedings of the 34th International Conference on Machine Learning - Vol. 70, 1263–1272 (JMLR.org, 2017).
• Gómez-Bombarelli, R. et al. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent. Sci. 4, 268–276 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Menden, M. P. et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS ONE 8, e61318 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Chang, Y. et al. Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature. Sci. Rep. 8, 8857 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Way, G. P. & Greene, C. S. Extracting a biologically relevant latent space from cancer transcriptomes with variational autoencoders. Pac. Symp. Biocomput 23, 80–91 (2018).
  PubMed PubMed Central Google Scholar
• Rampášek, L. et al Improving drug response prediction via modeling of drug perturbation effects. Bioinformatics. https://doi.org/10.1093/bioinformatics/btz158 (2019).
• Dincer, A. B., Celik, S., Hiranuma, N. & Lee, S.-I. DeepProfile: deep learning of cancer molecular profiles for precision medicine. bioRxiv 278739. https://doi.org/10.1101/278739 (2018).
• Chiu, Y.-C. Predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC Med. Genomics 12, 119 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013).
  Article CAS PubMed Google Scholar
• Jenh, C. H., Geyer, P. K., Baskin, F. & Johnson, L. F. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol. Pharmacol. 28, 80–85 (1985).
  CAS PubMed Google Scholar
• Berger, S. H., Jenh, C. H., Johnson, L. F. & Berger, F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 28, 461–467 (1985).
  CAS PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).
  Article CAS PubMed Google Scholar
• Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
  Article CAS PubMed Google Scholar
• Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 12, 587–598 (2012).
  Article CAS PubMed Google Scholar
• Meijer, C. et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52, 6885–6889 (1992).
  CAS PubMed Google Scholar
• Housman, G. et al. Drug resistance in cancer: an overview. Cancers 6, 1769–1792 (2014).
  Article PubMed PubMed Central Google Scholar
• Sun, X.-X. & Yu, Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol. Sin. 36, 1219–1227 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Malhotra, V. & Perry, M. C. Classical chemotherapy: mechanisms, toxicities and the therapeutc window. Cancer Biol. Ther. 2, 1–3 (2003).
  Article Google Scholar
• Blackadar, C. B. Historical review of the causes of cancer. World J. Clin. Oncol. 7, 54–86 (2016).
  Article PubMed PubMed Central Google Scholar
• Bertram, J. S. The molecular biology of cancer. Mol. Asp. Med. 21, 167–223 (2000).
  Article CAS Google Scholar
• Sun, W., Sanderson, P. E. & Zheng, W. Drug combination therapy increases successful drug repositioning. Drug Discov. Today 21, 1189–1195 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Hecht, J. R. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680 (2009).
  Article CAS PubMed Google Scholar
• Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med 360, 563–572 (2009).
  Article CAS PubMed Google Scholar
• Durand, A. et al. Contextual bandits for adapting treatment in a mouse model of de novo carcinogenesis. In Proc. 3rd Machine Learning for Healthcare Conference (eds. Doshi-Velez, F. et al.) Vol. 85, 67–82 (PMLR, 2018).
• Rationalizing combination therapies. Nat. Med. 23, 1113 (2017).
• He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. Methods Mol. Biol. 1711, 351–398 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose–response matrix data. Bioinformatics 33, 2413–2415 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Bliss, C. I. The toxicity of poisons applied jointly 1. Ann. Appl. Biol. 26, 585–615 (1939).
  Article CAS Google Scholar
• Li, X. et al. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artif. Intell. Med. 83, 35–43 (2017).
  Article PubMed Google Scholar
• Gayvert, K. M. et al. A computational approach for identifying synergistic drug combinations. PLoS Comput. Biol. 13, e1005308 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Weiss, A. et al. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18, 233–244 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Nowak-Sliwinska, P. et al. Optimization of drug combinations using Feedback System Control. Nat. Protoc. 11, 302–315 (2016).
  Article CAS PubMed Google Scholar
• Preuer, K. et al. DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. Bioinformatics 34, 1538–1546 (2018).
  Article CAS PubMed Google Scholar
• Fangfang Xia et al. Predicting tumor cell line response to drug pairs with deep learning. In Computational Approaches for Cancer Workshop at SC17. Available at: http://www.scworkshops.net/cancer2017/ (2017). (Accessed 20 Nov 2018).
• Holbeck, S. L. et al. The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. 77, 3564–3576 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Mauri, A., Consonni, V., Pavan, M. & Todeschini, R. Dragon software: an easy approach to molecular descriptor calculations. Match 56, 237–248 (2006).
  CAS Google Scholar
• Hwang, B., Lee, J. H. & Bang, D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp. Mol. Med. 50, 96 (2018).
  Article PubMed Central CAS Google Scholar
• Ortega, M. A. et al. Using single-cell multiple omics approaches to resolve tumor heterogeneity. Clin. Transl. Med. 6, 46 (2017).
  Article PubMed PubMed Central Google Scholar
• Ross, E. M. & Markowetz, F. OncoNEM: inferring tumor evolution from single-cell sequencing data. Genome Biol. 17, 69 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Jahn, K., Kuipers, J. & Beerenwinkel, N. Tree inference for single-cell data. Genome Biol. 17, 86 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Roth, A. et al. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat. Methods 13, 573–576 (2016).
  Article CAS PubMed Google Scholar
• Qi, R., Ma, A., Ma, Q. & Zou, Q. Clustering and classification methods for single-cell RNA-sequencing data. Brief. Bioinform. https://doi.org/10.1093/bib/bbz062 (2019).
• Shalek, A. K. & Benson, M. Single-cell analyses to tailor treatments. Sci. Transl. Med. 9, eaan4730 (2017).
• Zhu, S., Qing, T., Zheng, Y., Jin, L. & Shi, L. Advances in single-cell RNA sequencing and its applications in cancer research. Oncotarget 8, 53763–53779 (2017).
  Article PubMed PubMed Central Google Scholar
• Baran-Gale, J., Chandra, T. & Kirschner, K. Experimental design for single-cell RNA sequencing. Brief. Funct. Genomics 17, 233–239 (2018).
  Article CAS PubMed Google Scholar
• Suzuki, A. et al. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome Biol. 16, 66 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kim, K.-T. et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 17, 80 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013).
  Article CAS PubMed Google Scholar
• Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).
  PubMed PubMed Central Google Scholar
• Amodio, M. et al. Exploring single-cell data with deep multitasking neural networks. bioRxiv 237065. https://doi.org/10.1101/237065 (2018).
• Ding, J., Condon, A. & Shah, S. P. Interpretable dimensionality reduction of single cell transcriptome data with deep generative models. Nat. Commun. 9, 2002 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, D. & Gu, J. VASC: dimension reduction and visualization of single cell RNA sequencing data by deep variational autoencoder. bioRxiv 199315. https://doi.org/10.1101/199315 (2017).
• Risso, D. et al. clusterExperiment and RSEC: A Bioconductor package and framework for clustering of single-cell and other large gene expression datasets. PLoS Comput. Biol. 14, e1006378 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708–718 (2017).
  Article CAS PubMed Google Scholar
• Anchang, B. et al. DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. Proc. Natl Acad. Sci. USA 115, E4294–E4303 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333–337 (2016).
  Article CAS PubMed Google Scholar
• Hatzis, C. et al. Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res. 74, 4016–4023 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hamilton, W. et al. Inductive representation learning on large graphs. In Neural Information Processing Systems 1024–1034 (Curran Associates, Inc., 2017).
• Kearnes, S., McCloskey, K., Berndl, M., Pande, V. & Riley, P. Molecular graph convolutions: moving beyond fingerprints. J. Comput. Aided Mol. Des. 30, 595–608 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Hertel, L., Barth, E., Kaster, T. & Martinetz, T. Deep convolutional neural networks as generic feature extractors. In 2015 International Joint Conference on Neural Networks (IJCNN). https://doi.org/10.1109/ijcnn.2015.7280683 (2015).
• Zoph, B. & Le, Q. V. Neural architecture search with reinforcement learning. Preprint at https://arxiv.org/abs/1611.01578 (2016).
• Li, L. & Talwalkar, A. Random search and reproducibility for neural architecture search. Preprint at https://arxiv.org/abs/1902.07638 (2019).
• Rampášek, L., Hidru, D., Smirnov, P., Haibe-Kains, B. & Goldenberg, A. Dr.VAE: Improving drug response prediction via modeling of drug perturbation effects. Bioinformatics. https://doi.org/10.1093/bioinformatics/btz158 (2019).
• Zhang, Z. et al. Deep learning in omics: a survey and guideline. Brief. Funct. Genomics 18, 41–57 (2019).
  Article CAS PubMed Google Scholar
• Ivanov, A. A., Khuri, F. R. & Fu, H. Targeting protein–protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 34, 393–400 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Smirnov, P. et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics 32, 1244–1246 (2016).
  Article CAS PubMed Google Scholar
• Cokelaer, T. et al. GDSCTools for mining pharmacogenomic interactions in cancer. Bioinformatics. https://doi.org/10.1093/bioinformatics/btx744 (2017).
• Rajapakse, V. N., Luna, A., Yamade, M., Loman, L. & Varma, S. Integrative analysis of pharmacogenomics in major cancer cell line databases using CellMinerCDB. bioRxiv https://doi.org/10.1101/292904 (2018).
• Gupta, S. et al. Prioritization of anticancer drugs against a cancer using genomic features of cancer cells: A step towards personalized medicine. Sci. Rep. 6, 23857 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Mer, A. S. et al. Integrative pharmacogenomics analysis of patient derived xenografts. Cancer Res. 471227. https://doi.org/10.1101/471227 (2019).
• Lee, J.-K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399–1411 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• He, X., Folkman, L. & Borgwardt, K. Kernelized rank learning for personalized drug recommendation. Bioinformatics 34, 2808–2816 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Deshwar, A. G. et al. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 16, 35 (2015).
  Article PubMed PubMed Central Google Scholar
• Jiang, Y., Qiu, Y., Minn, A. J. & Zhang, N. R. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc. Natl Acad. Sci. USA 113, E5528–E5537 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• El-Kebir, M., Satas, G., Oesper, L. & Raphael, B. J. Inferring the mutational history of a tumor using multi-state perfect phylogeny mixtures. Cell Syst. 3, 43–53 (2016).
  Article CAS PubMed Google Scholar
• Satas, G. & Raphael, B. J. Tumor phylogeny inference using tree-constrained importance sampling. Bioinformatics 33, i152–i160 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Oesper, L., Satas, G. & Raphael, B. J. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics 30, 3532–3540 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Y. et al. DCDB 2.0: a major update of the drug combination database. Database 2014, bau124–bau124 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• O’Neil, J. et al. An unbiased oncology compound screen to identify novel combination strategies. Mol. Cancer Ther. 15, 1155–1162 (2016).
  Article PubMed CAS Google Scholar